Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Characteristics, Treatment and Outcome of 15 to 18 Years-Old Adolescents with Chronic Myeloid Leukemia (CML): The Experience of the International Registry of Childhood CML (I-CML-Ped Study)

Morgane Froment, Meinolf Suttorp, Stéphanie Ragot, Hélène Deutsch, Violaine Goyeau, Barbara De Moerloose, Silvia Regina Brandalise, Marina Borisevich, Petr Sedlacek, Adalet Meral Gunes, Birgitte Lausen, Antonio Molines Honrubia, Gordana Jakovljevic, Birgitta Versluys, Krzysztof Kalwak, Andrea Hraskova, Frederic Millot

Blood (2021) 138 (Supplement 1): 3602.

https://doi.org/10.1182/blood-2021-150438

Published: 2021

Journal Articles

Origin, functional role, and clinical impact of Fanconi anemia FANCA mutations

Blood (2011) 117 (14): 3759–3769.

https://doi.org/10.1182/blood-2010-08-299917

Published: 2011

Includes: Supplemental data

Journal Articles

Results of PETHEMA LAL-BR-01 Protocol for Low-Risk (LR) Acute Lymphoblastic Leukemia (ALL) In Children

Josep-Maria Ribera, MD, PhD, Albert Oriol, MD, Mireia Morgades, PhD, Pilar Bastida, MD, Olga Garcia, PhD, Alvaro Lasaletta, MD, Jose-Luis Fuster, MD, Elvira Gonzalez-Valentin, MD, Inmaculada Soto, MD, Ana Carbone, MD, Antonio Molines, MD, Izaskun Egurbide, MD, Andres Llorente, MD, Esmeralda Benitez, MD, Luis Madero, MD, PhD, Jose Sanchez de Toledo, MD, PhD

Blood (2010) 116 (21): 4334.

https://doi.org/10.1182/blood.V116.21.4334.4334

Published: 2010

Journal Articles

One Year Reinductions with Vincristine, Asparaginase and Prednisone as Post-Remission Therapy Improves Outcome in Children with Intermediate Risk (IR) Acute Lymphoblastic Leukemia (ALL).

Albert Oriol, MD, Pilar Bastida, MD, Olga García, Carlota Calvo, Juan-Manuel Perez-Hurtado, Maria-Elvira González Valentin, Jose Luis Fuster, MD, Izaskun Egurbide, Victoria Martin-Reina, Antonio Molines, MD, Javier Lassaletta, Miguel-Angel Sanz, Mar Tormo, Mercedes Carnero, Juan-José Ortega, Josep-Maria Ribera, MD, PhD

Blood (2009) 114 (22): 2026.

https://doi.org/10.1182/blood.V114.22.2026.2026

Published: 2009

Journal Articles

Treatment with All- Trans Retinoic Acid and Anthracycline Monochemotherapy in Children with Acute Promyelocytic Leukemia: Analysis of Three Sequential Multicenter Trials of the PETHEMA Group

Luis Madero, Pau Montesinos, MD, Pilar Bastida, MD, Amparo Verdeguer, MD, Javier De la Serna, MD, Antonio Molines, MD, Purificacion Garcia, MD, Jose Luis Fuster, MD, Maria jose Allegue, MD, Rafael Rojas, MD, Miguel A. Sanz, MD, PhD

Blood (2008) 112 (11): 137.

https://doi.org/10.1182/blood.V112.11.137.137

Published: 2008

Journal Articles

Comparison of Intensive Chemotherapy (CHT), Allogeneic (ALLO) or Autologous (AUTO) Stem Cell Transplantation (SCT) as Post-Remission Treatment for Children with Very High-Risk Acute Lymphoblastic Leukemia (VHR-ALL). Final Results of the PETHEMA ALL-93 Trial.

Josep-Maria Ribera, PhD, Juan-Jose Ortega, MD, Albert Oriol, MD, Pilar Bastida, MD, Carlota Calvo, MD, Jose-María Perez-Hurtado, MD, Maria-Elvira González-Valentin, MD, Vicky Martin-Reina, MD, Antonio Molines, MD, Fernando Ortega-Rivas, MD, Maria-Pilar Queipo, MD, Concepción Rivas, MD, Izaskun Egurbide, MD, Inmaculada Heras, MD, Concepción Poderos, MD, Eva Martínez-Revuelta, MD, Jose-Maria Guinea, MD, Eloy del Potro, MD, Guillermo Deben, MD

Blood (2005) 106 (11): 173.

https://doi.org/10.1182/blood.V106.11.173.173

Published: 2005

NARROW

Characteristics, Treatment and Outcome of 15 to 18 Years-Old Adolescents with Chronic Myeloid Leukemia (CML): The Experience of the International Registry of Childhood CML (I-CML-Ped Study)

Origin, functional role, and clinical impact of Fanconi anemia FANCA mutations

Results of PETHEMA LAL-BR-01 Protocol for Low-Risk (LR) Acute Lymphoblastic Leukemia (ALL) In Children

One Year Reinductions with Vincristine, Asparaginase and Prednisone as Post-Remission Therapy Improves Outcome in Children with Intermediate Risk (IR) Acute Lymphoblastic Leukemia (ALL).

Treatment with All- Trans Retinoic Acid and Anthracycline Monochemotherapy in Children with Acute Promyelocytic Leukemia: Analysis of Three Sequential Multicenter Trials of the PETHEMA Group

Comparison of Intensive Chemotherapy (CHT), Allogeneic (ALLO) or Autologous (AUTO) Stem Cell Transplantation (SCT) as Post-Remission Treatment for Children with Very High-Risk Acute Lymphoblastic Leukemia (VHR-ALL). Final Results of the PETHEMA ALL-93 Trial.

Email alerts

ASH Publications

American Society of Hematology

Characteristics, Treatment and Outcome of 15 to 18 Years-Old Adolescents with Chronic Myeloid Leukemia (CML): The Experience of the International Registry of Childhood CML (I-CML-Ped Study)

Origin, functional role, and clinical impact of Fanconi anemia FANCA mutations

Results of PETHEMA LAL-BR-01 Protocol for Low-Risk (LR) Acute Lymphoblastic Leukemia (ALL) In Children

One Year Reinductions with Vincristine, Asparaginase and Prednisone as Post-Remission Therapy Improves Outcome in Children with Intermediate Risk (IR) Acute Lymphoblastic Leukemia (ALL).

Treatment with All- Trans Retinoic Acid and Anthracycline Monochemotherapy in Children with Acute Promyelocytic Leukemia: Analysis of Three Sequential Multicenter Trials of the PETHEMA Group

Comparison of Intensive Chemotherapy (CHT), Allogeneic (ALLO) or Autologous (AUTO) Stem Cell Transplantation (SCT) as Post-Remission Treatment for Children with Very High-Risk Acute Lymphoblastic Leukemia (VHR-ALL). Final Results of the PETHEMA ALL-93 Trial.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only